Drug:
Reaction: PRURITUS
20250101 - 20251231
No. 1001 - 1100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1001 | 25091350 |
US |
46 | 2 |
Pruritus, Skin haemorrhage, |
||||
DUPILUMAB, |
||||
| 1002 | 25091358 |
US |
2 | |
Pruritus, Eye disorder, Eyelid disorder, Drug ineffective, |
||||
DUPILUMAB, APIXABAN, EMPAGLIFLOZIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, HYDROXYZINE PAMOATE, CARVEDILOL, FUROSEMIDE, CETIRIZINE HYDROCHLORIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, CLOPIDOGREL, MELATONIN, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, CYANOCOBALAMIN, GLUCAGON, MIRTAZAPINE, ALBUTEROL SULFATE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, INSULIN ASPART, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, FLUTICASONE PROPIONATE, DICYCLOMINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, LINACLOTIDE, MECLIZINE HYDROCHLORIDE, MECLIZINE HCL, MECLIZINE, FEXOFENADINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE, AZELASTINE, LISINOPRIL, ALBUTEROL SULFATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MECLIZINE HYDROCHLORIDE, MECLIZINE HCL, MECLIZINE, MONTELUKAST SODIUM, |
||||
| 1003 | 25091375 |
US |
49 | 2 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1004 | 25091408 |
US |
56 | 2 |
Pruritus, Erythema, Injection site bruising, |
||||
DUPILUMAB, ESCITALOPRAM, PHENTERMINE HYDROCHLORIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LISINOPRIL, |
||||
| 1005 | 25091424 |
US |
42 | 1 |
Sleep disorder due to a general medical condition, Rebound atopic dermatitis, Dry skin, Acne, Pruritus, Diarrhoea, Gastrointestinal sounds abnormal, Vomiting, Urticaria, Inappropriate schedule of product administration, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 1006 | 25091425 |
US |
68 | 2 |
Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1007 | 25091428 |
US |
88 | 2 |
Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1008 | 25091430 |
US |
82 | 1 |
Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1009 | 25091435 |
US |
28 | 2 |
Dyspnoea, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1010 | 25091441 |
US |
45 | 2 |
Dermatitis, Pruritus, Scratch, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1011 | 25091444 |
US |
11 | 1 |
Pruritus, Rash macular, Eczema, Illness, Gastroenteritis viral, |
||||
DUPILUMAB, |
||||
| 1012 | 25091448 |
US |
35 | 1 |
Dermatitis atopic, Pruritus, Skin swelling, Ocular hyperaemia, Injection site pain, Injection site swelling, |
||||
DUPILUMAB, |
||||
| 1013 | 25091482 |
US |
1 | |
Erythema of eyelid, Therapeutic response shortened, Erythema, Eczema, Rash, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1014 | 25091496 |
US |
27 | 2 |
Skin haemorrhage, Skin weeping, Skin fissures, Dry skin, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 1015 | 25091500 |
US |
1 | 1 |
Rebound eczema, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 1016 | 25091518 |
US |
39 | 2 |
Eczema, Dry skin, Pruritus, Inflammation, |
||||
DUPILUMAB, |
||||
| 1017 | 25091534 |
US |
39 | 2 |
Pruritus, Injection site pain, |
||||
DUPILUMAB, |
||||
| 1018 | 25091554 |
US |
14 | 1 |
Burning sensation, Pruritus, Erythema of eyelid, Erythema, Injection site pain, |
||||
DUPILUMAB, |
||||
| 1019 | 25091566 |
US |
79 | 1 |
Eczema, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 1020 | 25091567 |
US |
67 | 1 |
Blood pressure abnormal, Rash macular, Dry skin, Haemorrhage, Skin exfoliation, Pruritus, Dizziness, Endodontic procedure, Product dose omission in error, |
||||
DUPILUMAB, APIXABAN, LISINOPRIL, |
||||
| 1021 | 25091575 |
US |
50 | 2 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1022 | 25091595 |
US |
8 | 1 |
Insomnia, Eczema, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 1023 | 25091600 |
US |
31 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Dermatitis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1024 | 25091611 |
US |
54 | 2 |
Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1025 | 25091631 |
US |
1 | 1 |
Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 1026 | 25091645 |
US |
54 | 1 |
Eczema, Pruritus, Scratch, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1027 | 25091649 |
US |
65 | 2 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1028 | 25091670 |
US |
2 | |
Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 1029 | 25091696 |
US |
33 | 1 |
Eczema, Rash, Pruritus, |
||||
DUPILUMAB, |
||||
| 1030 | 25091698 |
US |
23 | 2 |
Pruritus, Therapeutic response decreased, |
||||
DUPILUMAB, MONTELUKAST, PREGABALIN, |
||||
| 1031 | 25091709 |
US |
38 | 1 |
Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 1032 | 25091711 |
US |
77 | 2 |
Dry skin, Pruritus, Injection site pain, Product use in unapproved indication, |
||||
DUPILUMAB, LEVOTHYROXINE SODIUM, |
||||
| 1033 | 25091715 |
US |
86 | 2 |
Fatigue, Pruritus, |
||||
DUPILUMAB, |
||||
| 1034 | 25091726 |
US |
82 | 2 |
Dry skin, Pruritus, Dry eye, |
||||
DUPILUMAB, |
||||
| 1035 | 25091735 |
US |
51 | 2 |
Dermatitis atopic, Rash, Pruritus, Erythema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1036 | 25091738 |
US |
28 | 2 |
Pruritus, Eczema, |
||||
DUPILUMAB, |
||||
| 1037 | 25091739 |
US |
3 | 1 |
Eczema, Insomnia, Condition aggravated, Pruritus, |
||||
DUPILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, MUPIROCIN, MUPIROCIN CALCIUM, |
||||
| 1038 | 25091746 |
US |
65 | 1 |
Rash, Erythema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1039 | 25091749 |
US |
64 | 1 |
Pruritus, Skin haemorrhage, Rash, |
||||
DUPILUMAB, |
||||
| 1040 | 25091760 |
US |
56 | 2 |
Pruritus, Injection site pain, Off label use, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1041 | 25091771 |
US |
1 | |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1042 | 25091780 |
US |
46 | 2 |
Dry skin, Skin haemorrhage, Skin weeping, Skin fissures, Eczema, Sleep disorder due to a general medical condition, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 1043 | 25091786 |
US |
6 | 1 |
Eczema, Pruritus, Dry skin, Skin exfoliation, Skin fissures, Therapeutic response shortened, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 1044 | 25091790 |
US |
5 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1045 | 25091792 |
US |
15 | 1 |
Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 1046 | 25091891 |
US |
62 | 2 |
Spinal fusion surgery, Pruritus, Inappropriate schedule of product administration, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 1047 | 25092076 |
US |
60 | 2 |
Skin exfoliation, Pruritus, Rash, Pruritus, Scratch, Scab, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1048 | 25093829 |
1 | ||
Swelling, Diarrhoea, Dizziness, Pruritus, Therapy cessation, |
||||
TRALOKINUMAB-LDRM, |
||||
| 1049 | 25094001 |
27 | 2 | |
Throat irritation, Pruritus, Dyspnoea, Infusion related reaction, |
||||
CEFTRIAXONE, |
||||
| 1050 | 25094169 |
65 | 2 | |
Pruritus, Neuropathy peripheral, |
||||
TRASTUZUMAB-ANNS, PERTUZUMAB, |
||||
| 1051 | 25094175 |
76 | 2 | |
Rash erythematous, Pruritus, Rash, Rash, |
||||
LENALIDOMIDE, |
||||
| 1052 | 25094308 |
63 | 1 | |
Pruritus, Rash erythematous, Rash, Rash, Therapy change, |
||||
| 1053 | 25096623 |
53 | 1 | |
Rash, Pruritus, Infusion related reaction, |
||||
| 1054 | 25096683 |
64 | 2 | |
Pruritus, Throat tightness, Chest discomfort, Nausea, |
||||
TIRZEPATIDE, |
||||
| 1055 | 25081735 |
US |
61 | 2 |
Spinal cord compression, Pruritus, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 1056 | 25081745 |
CA |
43 | 2 |
Pulmonary fibrosis, Osteoarthritis, Osteoporosis, Pain, Pain in extremity, Pemphigus, Pericarditis, Peripheral swelling, Prescribed overdose, Prescribed underdose, Product use in unapproved indication, Product use issue, Pruritus, Psoriasis, Psoriatic arthropathy, Pyrexia, Pneumonia, Oedema peripheral, Intentional product use issue, Off label use, Rash, Red blood cell sedimentation rate increased, Retinitis, Rheumatic fever, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, OXYCODONE, OXYCODONE, OXYCODONE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, ERENUMAB-AOOE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, SECUKINUMAB, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 1057 | 25081858 |
US |
2 | |
Pruritus, |
||||
| 1058 | 25081885 |
US |
2 | |
Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1059 | 25081942 |
US |
20 | 1 |
Rebound atopic dermatitis, Product dose omission issue, Pruritus, |
||||
DUPILUMAB, |
||||
| 1060 | 25082021 |
US |
61 | 2 |
Ocular hyperaemia, Eczema, Skin swelling, Erythema, Pruritus, Injection site erythema, Injection site pruritus, Eye pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1061 | 25082057 |
US |
2 | |
Pruritus, Erythema, |
||||
OCRELIZUMAB, |
||||
| 1062 | 25082077 |
US |
78 | 2 |
Hepatic fibrosis, Pancytopenia, Ascites, Hepatic cancer, Gastrointestinal disorder, Oesophageal disorder, Osteoporosis, Nausea, Vomiting, Irritable bowel syndrome, Faeces discoloured, Haemorrhoids, Blood alkaline phosphatase increased, Pruritus, Drug ineffective, |
||||
OBETICHOLIC ACID, OBETICHOLIC ACID, URSODIOL, URSOSIOL, APIXABAN, FOLIC ACID, CALCIUM CARBONATE, ANTACID, AMLODIPINE, ERGOCALCIFEROL, CARVEDILOL, FUROSEMIDE, LATANOPROST, PANTOPRAZOLE, SPIRONOLACTONE, |
||||
| 1063 | 25082082 |
CA |
68 | 2 |
Pneumonia, Gastrooesophageal reflux disease, Skin plaque, Condition aggravated, Aphonia, Nasal congestion, Cough, Dry eye, Headache, Dry mouth, Dyspnoea, Malaise, Osteoporosis, Ear pain, Drug intolerance, Influenza, Oropharyngeal pain, Fatigue, Pruritus, |
||||
OBETICHOLIC ACID, OBETICHOLIC ACID, URSODIOL, URSOSIOL, URSODIOL, URSOSIOL, URSODIOL, URSOSIOL, URSODIOL, URSOSIOL, URSODIOL, URSOSIOL, URSODIOL, URSOSIOL, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, TELMISARTAN, |
||||
| 1064 | 25082163 |
US |
62 | 2 |
Rash, Pruritus, |
||||
TOCILIZUMAB, |
||||
| 1065 | 25082185 |
US |
68 | 2 |
Memory impairment, Thirst, Pruritus, Erythema, Somnolence, Fatigue, Asthenia, Decreased appetite, Blood glucose increased, Alopecia, |
||||
BEVACIZUMAB-AWWB, BEVACIZUMAB, PEMBROLIZUMAB, PACLITAXEL, CARBOPLATIN, PALONOSETRON, PALONOSETRON HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, FOSAPREPITANT, FOSAPREPITANT DIMEGLUMINE, CETIRIZINE HYDROCHLORIDE, FAMOTIDINE, |
||||
| 1066 | 25082219 |
US |
5 | 1 |
Pruritus, Therapeutic product effect decreased, |
||||
DUPILUMAB, |
||||
| 1067 | 25082241 |
CA |
50 | 2 |
Pericarditis, Osteoarthritis, Sciatica, Treatment failure, Off label use, Urticaria, Musculoskeletal stiffness, Maternal exposure during pregnancy, Product use issue, Lower limb fracture, Lung disorder, Pemphigus, Rheumatoid factor positive, Oedema, Night sweats, Swollen joint count, Therapy non-responder, Type 2 diabetes mellitus, Rheumatoid arthritis, Nasopharyngitis, Swelling, Obesity, Malaise, Vomiting, Weight increased, Rheumatic fever, Stomatitis, Systemic lupus erythematosus, Paraesthesia, Wheezing, Peripheral swelling, Sleep disorder due to general medical condition, hypersomnia type, Muscle injury, Musculoskeletal pain, Prescribed overdose, Psoriatic arthropathy, Sinusitis, Muscle spasms, Mobility decreased, Pruritus, Pyrexia, Lower respiratory tract infection, Swollen joint count increased, Wound, Therapeutic product effect decreased, Rash, Peripheral venous disease, Pain, Pregnancy, Road traffic accident, Product use in unapproved indication, Tender joint count, |
||||
QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, RAMIPRIL, |
||||
| 1068 | 25082252 |
US |
2 | |
Alopecia, Pruritus, Stomatitis, Diarrhoea, Constipation, Nausea, Product odour abnormal, Product taste abnormal, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, |
||||
| 1069 | 25082255 |
US |
1 | |
Erythema, Pruritus, Skin burning sensation, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1070 | 25082303 |
US |
47 | 2 |
Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1071 | 25082324 |
US |
2 | |
Rash, Pruritus, |
||||
DESVENLAFAXINE, DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE, DESVENLAFAXINE SUCCINATE, |
||||
| 1072 | 25082355 |
US |
84 | 2 |
Pruritus, Joint swelling, |
||||
LENALIDOMIDE, |
||||
| 1073 | 25082378 |
US |
6 | 2 |
Rebound eczema, Fungal infection, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 1074 | 25082379 |
US |
30 | 2 |
Sleep disorder, Dry skin, Lacrimation increased, Migraine, Pruritus, |
||||
DUPILUMAB, |
||||
| 1075 | 25082483 |
US |
1 | |
Rash vesicular, Pruritus, Urticaria, Erythema, |
||||
EVOLOCUMAB, EVOLOCUMAB, ROSUVASTATIN, |
||||
| 1076 | 25082495 |
US |
13 | 2 |
Pruritus, Dry skin, Skin fissures, Eye pruritus, |
||||
DUPILUMAB, |
||||
| 1077 | 25082501 |
US |
||
Throat tightness, Pruritus, |
||||
| 1078 | 25082502 |
US |
||
Hypersensitivity, Pruritus, Dizziness, Lip swelling, Urticaria, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, AMLODIPINE, ROSUVASTATIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DULOXETINE HYDROCHLORIDE, DULOXETINE, INSULIN GLARGINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 1079 | 25082507 |
CA |
13 | 1 |
Pyrexia, Tachycardia, Hypoxia, Tachypnoea, Rash, Angioedema, Anaphylactic reaction, Pruritus, Chills, Dyspnoea, Pain in extremity, Nausea, Hypotension, |
||||
| 1080 | 25082557 |
US |
2 | |
Illness, Infection, Decreased appetite, Pain, Pruritus, Swelling, |
||||
OMALIZUMAB, |
||||
| 1081 | 25082592 |
US |
1 | |
Dry skin, Pruritus, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, PANTOPRAZOLE SODIUM, |
||||
| 1082 | 25082686 |
US |
41 | 1 |
Erythema, Pruritus, Dry eye, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1083 | 25082691 |
US |
2 | |
Pruritus, Sinusitis, Rash, Hypersensitivity, Cough, |
||||
RIVAROXABAN, RIVAROXABAN, |
||||
| 1084 | 25082829 |
US |
68 | 2 |
Pruritus, Headache, Nasal congestion, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1085 | 25082837 |
US |
57 | 2 |
Upper limb fracture, Loss of consciousness, Influenza, Face injury, Rib fracture, Therapeutic product effect incomplete, Nail disorder, Fall, Headache, Nasopharyngitis, Sinus congestion, Paranasal sinus discomfort, Dyspnoea, Pruritus, Sinus headache, |
||||
RISANKIZUMAB-RZAA, |
||||
| 1086 | 25082855 |
US |
50 | 2 |
Pruritus, Rash, Erythema, Eye pruritus, Paraesthesia, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1087 | 25082862 |
US |
74 | 1 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1088 | 25082880 |
US |
59 | 2 |
Dry skin, Pruritus, Skin burning sensation, Arthralgia, |
||||
DUPILUMAB, |
||||
| 1089 | 25082911 |
US |
1 | |
Pruritus, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1090 | 25082981 |
GB |
2 | |
Abdominal distension, Pruritus, |
||||
VARENICLINE, VARENICLINE TARTRATE, |
||||
| 1091 | 25083011 |
GB |
||
Pruritus, |
||||
VARENICLINE, VARENICLINE TARTRATE, |
||||
| 1092 | 25083086 |
CA |
25 | 2 |
Angioedema, Anxiety, Body temperature increased, Cough, Drug hypersensitivity, Flushing, Heart rate increased, Illness, Inappropriate schedule of product administration, Nausea, Pruritus, Sinusitis, Stress, Swelling, Urticaria, Weight decreased, Weight increased, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, MONTELUKAST SODIUM, |
||||
| 1093 | 25083124 |
US |
16 | 2 |
Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 1094 | 25083269 |
US |
41 | 1 |
Dry skin, Sleep disorder, Pruritus, |
||||
DUPILUMAB, |
||||
| 1095 | 25083270 |
US |
25 | 2 |
Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1096 | 25083366 |
GB |
80 | 1 |
Rash macular, Pruritus, Product substitution, |
||||
SIMVASTATIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 1097 | 25083426 |
CA |
25 | 2 |
Paraesthesia, Pruritus, Rash macular, Swelling face, |
||||
OFATUMUMAB, OFATUMUMAB, |
||||
| 1098 | 25083436 |
US |
86 | 1 |
Bone pain, Chest discomfort, Pyrexia, Erythema, Pruritus, Fatigue, Chest pain, |
||||
PACRITINIB, |
||||
| 1099 | 25083448 |
US |
7 | 2 |
Pruritus, |
||||
DUPILUMAB, |
||||
| 1100 | 25083484 |
US |
78 | 2 |
Injection site warmth, Injection site erythema, Dermatitis atopic, Pruritus, Rash erythematous, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28